Businesses that spend the highest amounts annually on research and development, anywhere from $10 billion to over $100 billion, are often among the least clear
Tag: pharma
Industry Lines are Blurring When it Comes to Sources of Innovation and rights, especially in AI
The U.S. and the Americas continue to be the leading source in key areas of innovation such as pharmaceuticals, semiconductors, information technologies and medical products.
Identifying Return on IP (ROIP) is More Art than Financial Science; What’s Being Overlooked?
It’s easy to appreciate intellectual property licensing. C-level executives and investors of all types are among the many who attracted to the revenue and smitten
Breaking Patents — A Futile Response to the Global Pandemic That Benefits Businesses, Not People
When it comes to intellectual property rights, nothing impedes like success. President Joe Biden last week threw his support behind the World Health Organizations proposal
2014 Patent Verdicts Suggest the Best IP Rights Remain Valuable if More Difficult to Monetize
While $50 million-and-up patent verdicts were up in the first half of 2014, there were only two wins higher than $131M and none from NPEs.
Pharma Cos Face "Patent Cliff" as Protection Expires
Ten Blockbusters will End in Two Years – An article in Daily Finance says that patents that are expiring on many top-selling drugs will cause pharmaceutical
ipcloseup.com 